QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:PTCT

PTC Therapeutics - PTCT Stock Forecast, Price & News

$51.72
-1.69 (-3.16%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$50.52
$53.29
50-Day Range
$25.60
$53.50
52-Week Range
$25.01
$54.29
Volume
701,288 shs
Average Volume
727,030 shs
Market Capitalization
$3.69 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.75

PTC Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
0.8% Upside
$52.13 Price Target
Short Interest
Bearish
10.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.73
Upright™ Environmental Score
News Sentiment
-0.26mentions of PTC Therapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$10,920 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.62) to ($4.05) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.16 out of 5 stars

Medical Sector

1078th out of 1,098 stocks

Pharmaceutical Preparations Industry

523rd out of 536 stocks

PTCT stock logo

About PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Analyst Ratings Changes

PTCT has been the topic of several analyst reports. Credit Suisse Group lifted their target price on PTC Therapeutics to $52.00 in a research report on Friday, July 22nd. Royal Bank of Canada lifted their target price on PTC Therapeutics from $42.00 to $46.00 and gave the company a "sector perform" rating in a research report on Thursday, June 23rd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, PTC Therapeutics has a consensus rating of "Hold" and a consensus price target of $51.75.

PTC Therapeutics Price Performance

NASDAQ:PTCT traded down $2.30 on Tuesday, reaching $51.11. 12,232 shares of the company's stock traded hands, compared to its average volume of 590,686. The company has a quick ratio of 1.59, a current ratio of 1.62 and a debt-to-equity ratio of 679.17. The stock has a 50-day simple moving average of $38.75 and a 200-day simple moving average of $37.95. The firm has a market cap of $3.65 billion, a PE ratio of -6.57 and a beta of 0.64. PTC Therapeutics has a 12 month low of $25.01 and a 12 month high of $54.29.

PTC Therapeutics (NASDAQ:PTCT - Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($2.13) EPS for the quarter, missing analysts' consensus estimates of ($1.66) by ($0.47). The business had revenue of $165.50 million for the quarter, compared to the consensus estimate of $162.53 million. PTC Therapeutics had a negative net margin of 89.89% and a negative return on equity of 10,562.67%. PTC Therapeutics's revenue was up 41.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.68) earnings per share. Equities research analysts forecast that PTC Therapeutics will post -5.62 earnings per share for the current year.

Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTCT Stock News Headlines

Oversold Conditions For PTC Therapeutics
See More Headlines
Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTCT Company Calendar

Last Earnings
8/04/2022
Today
8/09/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PTCT
Employees
1,177
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$52.13
High Stock Price Forecast
$76.00
Low Stock Price Forecast
$38.00
Forecasted Upside/Downside
+0.1%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Net Income
$-523,900,000.00
Pretax Margin
-89.93%
Return on Equity
-10,562.67%

Debt

Sales & Book Value

Annual Sales
$538.59 million
Book Value
$0.02 per share
Price / Book
2,586.00

Miscellaneous

Free Float
67,058,000
Market Cap
$3.69 billion
Optionable
Optionable
Beta
0.64














PTCT Stock - Frequently Asked Questions

Should I buy or sell PTC Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" PTCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PTCT, but not buy additional shares or sell existing shares.
View PTCT analyst ratings
or view top-rated stocks.

What is PTC Therapeutics' stock price forecast for 2022?

8 brokerages have issued 1 year target prices for PTC Therapeutics' shares. Their PTCT share price forecasts range from $38.00 to $76.00. On average, they anticipate the company's stock price to reach $52.13 in the next year. This suggests a possible upside of 3.0% from the stock's current price.
View analysts price targets for PTCT
or view top-rated stocks among Wall Street analysts.

How has PTC Therapeutics' stock performed in 2022?

PTC Therapeutics' stock was trading at $39.83 at the beginning of the year. Since then, PTCT shares have increased by 27.1% and is now trading at $50.62.
View the best growth stocks for 2022 here
.

When is PTC Therapeutics' next earnings date?

PTC Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our PTCT earnings forecast
.

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) released its quarterly earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($2.13) earnings per share for the quarter, missing the consensus estimate of ($1.66) by $0.47. The biopharmaceutical company earned $165.50 million during the quarter, compared to analysts' expectations of $162.53 million. PTC Therapeutics had a negative trailing twelve-month return on equity of 10,562.67% and a negative net margin of 89.89%. The company's revenue was up 41.8% compared to the same quarter last year. During the same period last year, the business earned ($1.68) earnings per share.

What guidance has PTC Therapeutics issued on next quarter's earnings?

PTC Therapeutics issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $700.00 million-$750.00 million, compared to the consensus revenue estimate of $722.95 million.

What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO?

24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees.

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD).

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

Who are PTC Therapeutics' major shareholders?

PTC Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Loomis Sayles & Co. L P (2.29%), TimesSquare Capital Management LLC (0.96%), Handelsbanken Fonder AB (0.73%), Redwood Investments LLC (0.66%), Candriam S.C.A. (0.28%) and Pinnacle Associates Ltd. (0.26%). Insiders that own company stock include Allan Steven Jacobson, Christine Marie Utter, Dawn Svoronos, Emily Luisa Hill, Eric Pauwels, Marcio Souza, Mark Elliott Boulding, Matthew B Klein, Matthew B Klein, Neil Gregory Almstead, Stephanie Okey and Stuart Walter Peltz.
View institutional ownership trends
.

How do I buy shares of PTC Therapeutics?

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PTC Therapeutics' stock price today?

One share of PTCT stock can currently be purchased for approximately $50.62.

How much money does PTC Therapeutics make?

PTC Therapeutics (NASDAQ:PTCT) has a market capitalization of $3.61 billion and generates $538.59 million in revenue each year. The biopharmaceutical company earns $-523,900,000.00 in net income (profit) each year or ($7.83) on an earnings per share basis.

How many employees does PTC Therapeutics have?

PTC Therapeutics employs 1,177 workers across the globe.

How can I contact PTC Therapeutics?

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The official website for the company is www.ptcbio.com. The biopharmaceutical company can be reached via phone at (908) 222-7000, via email at ehill@ptcbio.com, or via fax at 908-222-7231.

This page (NASDAQ:PTCT) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.